The conjugated drug industry, encompassing ADCs, RDCs, PDCs, SMDCs, and other novel conjugated therapies, has witnessed remarkable advancements in recent years. A report, inspired by Frost & Sullivan’s “Blue Book on the Status and Trends of the Conjugated Drug Industry,” provides a comprehensive overview of the industry’s development, market dynamics, and emerging trends.

Overview of Conjugated Drugs

1.  Antibody-Drug Conjugates (ADCs): 

ADC technology, proposed over a century ago, has matured significantly, resulting in a surge of clinical pipelines and market enthusiasm, particularly in the U.S., China, and Japan. ADCs consist of an antibody, linker, and payload that specifically target tumor antigens. Over three generations of technological iterations, site-specific conjugation techniques have become a focal point. These advancements have diversified ADC targets, antibodies, linkers, and payloads, influencing their pharmacological properties. Approved ADCs demonstrate exceptional efficacy, with a robust pipeline promising further optimization in targets, antibodies, linkers, and payloads, expanded indications, and combined therapeutic strategies.

2. Radionuclide-Drug Conjugates (RDCs): 

RDCs, comprising targeted vectors and radionuclides, offer integrated diagnostic and therapeutic capabilities for cancer. Notable breakthroughs include Novartis’ Pluvicto, the first approved RDC for mCRPC. A burgeoning pipeline and expanding radionuclide varieties signal a bright future, focusing on novel radionuclides, extended indications, and combined drug-device solutions.

3. Peptide-Drug Conjugates (PDCs): 

PDCs utilize peptides as targeting vectors, featuring a similar structure to ADCs but with distinct mechanisms of action. Their modular composition—peptide, linker, and payload—enables multifaceted optimization. With 20 active pipelines globally and drugs like RAB001 leading development, PDCs aim to refine structural design and broaden their application scope to advance precision medicine.

4. Small Molecule-Drug Conjugates (SMDCs): 

SMDCs couple small molecule ligands with cytotoxic agents, offering high tissue penetration, safety, and cost advantages. Currently, 22 active pipelines globally highlight their growing significance, with AST-3424 as a key representative. Future endeavors will focus on expanded clinical trials, optimized designs, broader indications, and combination therapies.

5. Other Emerging Conjugated Therapies:

This category includes ISACs, AOCs, APCs, and ACCs, representing early-stage innovations with diverse mechanisms and potential advantages. With 65 active pipelines globally and notable drugs like WTX212 and SGM101, these therapies offer transformative opportunities but face developmental challenges.

Key Drivers of Industry Growth

1. Policy Support: 

Governments are prioritizing ADC drug development through favorable policies, fostering industry growth at national and regional levels.

2. Medical Demand: 

Rising incidence of diseases targeted by ADCs is driving market growth as these therapies address critical unmet needs.

3. Capital Investment: 

Increased investment in the ADC sector, including acquisitions, collaborations, licensing deals, and IPOs, underscores the sector’s potential. The emergence of ADC contract development and manufacturing organizations (CDMOs) further accelerates progress.

Capital Market Performance

ADCs: 

The ADC sector continues to attract robust investment. Chinese companies are gaining traction, leveraging clinical and sales performance to drive full-industry-chain development. Multinational corporations like Pfizer have strategically expanded through acquisitions, including Seagen.

RDCs: 

Financing activities remain strong, with Chinese companies securing significant investments. Global competition intensifies as major players, such as Bristol-Myers Squibb, acquire innovative RDC developers like RayzeBio.

PDCs and SMDCs: 

Both sectors are drawing attention from enterprises and investors, with increasing clinical research and development activities aimed at unlocking their vast market potential.

Product Highlights from Hzymes Biotech

Hzymes Biotech offers a range of conjugated drug-related products and solutions, categorized as follows:

• Residual Detection Kits:

• Residual Host Cell DNA Extraction/qPCR/Protein Detection Kits
• Mag TR DNA Kits (e.g., HEK293, CHO, E.coli, Vero, etc.)
• CHO-K1 HCP ELISA Kit

• Exogenous/Process-Related Residue Detection:

• Mycoplasma Detection Kits.
• Recombinant Factor C Endotoxin Detection Kits
• Ultra Nuclease Assay Kits (ELISA and Fluorescence)
• Recombinant Trypsin Assay Kits

• Tool Enzymes:

• Trypsin, Ultra Nuclease, PNGase F, Proteinase K
• Recombinant Human Hyaluronidase

• Glycan Analysis Kits:

• N-Glycan Kits in various formats (single column, 96-well plate, 2AB)

These innovative tools and reagents enhance the development, optimization, and quality control processes for conjugated drugs, supporting industry stakeholders in addressing evolving challenges and demands.

Conclusion